Ligand Pharmaceuticals | LGND - Current Assets


Ligand Pharmaceuticals reported $865.42M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Agenus USD 95.28M 38.15M Mar/2026
Amgen USD 34.96B 3.49B Jun/2026
Anika Therapeutics USD 99.19M 5.63M Jun/2026
Arrowhead Research USD 1.67B 168.34M Jun/2026
Baxter International USD 6.99B 142M Jun/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Eli Lilly USD 64.67B 9.84B Jun/2026
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Enviri Corporation USD 722.11M 1.43M Mar/2026
Gilead Sciences USD 12.53B 6.11B Jun/2026
GlaxoSmithKline GBP 17.56B 202M Jun/2026
Glaxosmithkline GBP 17.76B 5.83B Mar/2026
Heron Therapeutics USD 228.98M 9.08M Mar/2026
Insmed USD 1.63B 20.75M Jun/2026
Intrexon USD 23.72M 45.04M Jun/2024
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
Ligand Pharmaceuticals USD 865.42M 33.14M Mar/2026
MacroGenics USD 182.52M 37.42M Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Pacira USD 615.21M 100.25M Jun/2026
Pfizer USD 41.36B 1.46B Jun/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Veracyte USD 574.78M 52.6M Jun/2026